Associate Professor, Medicine, Perelman School of Medicine
Oncology
Dr. Bruce J. Giantonio, MD
|
|
Give Review
Bruce Giantonio is an expert in the field of Oncology. He went to medical school at Georgetown University School of Medicine. Georgetown University School of Medicine has a rank of 49 in research and a 84 in primary care He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Doctor Bruce J. Giantonio, MD has written publications. He has 48 publications published with PubMed. The lastest publication is: 'Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion.' He accepts all Medicare patients.
Publications
- Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: A propensity score-matched Analysis.
- Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.
- A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangioCarcinoma.
- Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced Cancer.
- Characteristics associated with differences in survival among black and white women with breast Cancer.
- Bevacizumab in the treatment of metastatic colorectal Cancer (mCRC) in second- and third-line settings.
- Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly two-hour infusion in patients with advanced solid Tumors.
- Vinblastine and estramustine phosphate in metastatic renal cell Carcinoma: a phase II trial of the Fox Chase Network.
- Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular Carcinoma.
- Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenoCarcinoma.
- Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal Cancer: results from the Eastern Coope...
- Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal Cancer.
- Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal Cancer.
- The role of the Eastern Cooperative Oncology Group in establishing standards of Cancer care: over 50 years of progress through clinical research.
- Bevacizumab: current indications and future development for management of solid Tumors.
- Targeted therapies: Goldie-Coldman and bevacizumab beyond disease progression.
- Effect of bevacizumab in older patients with metastatic colorectal Cancer: pooled analysis of four randomized studies.
- Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced up...
- Concurrent RT with 5-FU/epirubicin and cisplatin or irinotecan for locally advanced upper GI adenoCarcinoma.
- Phase I trial of combretastatin a-4 phosphate with carboplatin.
- A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal Cancer.
- Gastrointestinal perforation and Cancer therapy: managing risk to achieve benefit.
- A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal Cancer: results from t...
- Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with Cancer: magnetic resonance imaging evidence for altered tumor ...
- Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies.
- Phase I trial of UFT/leucovorin and irinotecan in patients with advanced Cancer.
- Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials.
- Prostate Cancer.
- Genitourinary malignancy.
- Precursor CTL specific for retrovirus-induced T Lymphoma are found at high frequency in unprimed syngeneic mice.
- Phase I trial of ilmofosine as a 24 hour infusion weekly.
- Phase II study of topotecan in metastatic hormone-refractory prostate Cancer.
- Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell Carcinoma of...
- Adjuvant chemotherapy for breast Cancer in pregnancy: can recommendations be made with confidence.
- Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced Pancreatic ...
- Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate Cancer.
- Superantigen-targeted therapy: phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies.
- Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder Cancer.
- Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion.
- Follow-up of stage B and C colorectal Cancer in the United States and France.
- Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal Carcinoma and relapsed or refractory lymphoma: a report...
- A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced Tumors.
- Safety and efficacy of exisulind for treatment of recurrent prostate Cancer after radical prostatectomy.
- Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with Cancer.
- High rate of consent to bank biologic samples for future research: the Eastern Cooperative Oncology Group experience.
- Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced Cancer.
- Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced Cancer.
Schools
Georgetown University School Of Medicine
Fletcher Allen Health Care
Temple University Hospital
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Temple University Hospital -
University of Vermont - Fletcher Allen Health Care -
Georgetown University School of Medicine
Hospital
-
Hospital of the University of Pennsylvania
Drug Facts
| NPI NUMBER | 1255377198 | |
| NPPES Provider LastName | GIANTONIO | |
| NPPES Provider FirstName | BRUCE | |
| NPPES Provider ZIPCode | 191044206 | |
| NPPES Provider State | PA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 216.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1255377198 |
| Last Name Of The Provider | GIANTONIO |
| First Name Of The Provider | BRUCE |
| View All |
Similar Doctors
|
Dr. Seyfettin O. Alpdogan, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan D. Cheng, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Rushang D. Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Allen E. Terzian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert F. Ozols, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jianqing Lin, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. J Frederick Laucius, MD |
|
Dr. Deric C. Savior, MD
This Doctor is OpenDoctor Recommended.
|